ClinicalTrials.gg
CompletedNCT02865850Updated Jul 18, 2022Results posted

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

A Phase 3 interventional study of Vadadustat and Darbepoetin alfa in Anemia and Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 118 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-18.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
6th of 27
369 · median 60
Started
2016
with 4 others
Phase 3
14 of 27
none open now
Registered
10th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 6th largest by enrollment, is one of 5 that started in 2016, is one of 14 in phase 3, and was the 10th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).

Read the detailed description

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of Vadadustat versus Darbepoetin alfa for the correction or maintenance treatment in participants with anemia secondary to chronic kidney disease who have recently initiated dialysis treatment for end-stage renal disease.

03

Conditions studied

  • Anemia
  • Dialysis-Dependent Chronic Kidney Disease

Keywords

  • Vadadustat
  • AKB-6548
  • anemia
  • chronic kidney disease
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • kidney
  • renal
  • oral anemia treatment
  • hemoglobin
  • hypoxia-inducible factor
  • HIF
  • efficacy
  • safety
  • phase 3
  • cardiovascular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Initiated chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease within 16 weeks prior to Screening
  • Mean Screening between 8.0 and \<11.0 grams per deciliter (g/dL) (inclusive)
  • Serum ferritin ≥100 nanograms per deciliter (ng/mL) and TSAT ≥20% during Screening

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than chronic kidney disease or participants with active bleeding or recent blood loss
  • Red blood cells transfusion within 8 weeks prior to randomization
  • Anticipated to recover adequate kidney function to no longer require dialysis
  • Uncontrolled hypertension
  • Severe heart failure at Screening ( Class IV)
  • Acute coronary syndrome (hospitalization for unstable angina, myocardial infarction); surgical or percutaneous intervention for coronary, cerebrovascular, or peripheral artery disease (aortic or lower extremity); surgical or percutaneous valvular replacement or repair; sustained ventricular tachycardia; hospitalization for congestive heart failure; or stroke within 12 weeks prior to or during Screening.
  • Participants meeting the criteria of erythropoiesis-stimulating agent resistance within 8 weeks prior to or during Screening defined as follows

    1. epoetin: > 7700 units/dose three times per week or >23,000 units per week
    2. Darbepoetin alfa: >100 micrograms per week (mcg/week)
    3. methoxy polyethylene glycol-epoetin beta: >100 micrograms (mcg) every other week or >200 mcg/month
  • to Vadadustat, Darbepoetin alfa or any of their
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Drug: Vadadustat

  • Active comparator
    Darbepoetin alfa

    Drug: Darbepoetin alfa

Interventions

  • Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

    Also known as: AKB-6548

  • Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.

    Also known as: Aranesp

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)

    The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (\<9.5 versus ≥9.5 g/dL), geographic region (United States \[US\] versus European Union \[EU\] versus Rest of World \[ROW\]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 \[no CHF\] or I versus II or III) as covariates.

    Time frame: Baseline; Weeks 24 to 36

  2. Median Time to First Major Adverse Cardiovascular Event (MACE)

    MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 176 weeks

Secondary outcomes

  1. Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)

    The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (\<9.5 versus ≥9.5 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 \[no CHF\] or I versus II or III) as covariates.

    Time frame: Baseline; Weeks 40 to 52

  2. Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis

    MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 176 weeks

  3. Median Time to First Cardiovascular MACE

    MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 176 weeks

  4. Median Time to First Cardiovascular Death

    Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 176 weeks

  5. Median Time to First All-cause Mortality

    Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 176 weeks

Other outcomes

  1. Exploratory - Proportion of Participants With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)

    Time frame: Weeks 24 to 36

  2. Exploratory - Proportion of Time With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)

    Time frame: Weeks 24 to 36

  3. Exploratory - Proportion of Time With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)

    Time frame: Weeks 40 to 52

  4. Exploratory - Proportion of Participants With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)

    Time frame: Weeks 40 to 52

  5. Exploratory - Proportion of Participants With an Hb Increase of >1.0 g/dL From Baseline Visit

    Time frame: Baseline; up to Week 52

  6. Exploratory - Time to Achieve Hb Increase of >1.0 g/dL From Baseline Visit

    Time frame: Baseline; up to Week 52

  7. Exploratory - Mean Change in Hb Between Baseline (Mean Pretreatment Hb) and the Primary Evaluation Period (Mean Hb From Weeks 24 to 36) Stratified by Pre-baseline Erythropoiesis-stimulating Agent (ESA) Exposure

    Time frame: Baseline; Weeks 24 to 36

  8. Exploratory - Mean Monthly Dose of Intravenous (IV) Elemental Iron Administered in Participants Who Have Received IV Iron

    Time frame: Up to Week 52

  9. Exploratory - Proportion of Participants Receiving IV Iron Therapy

    Time frame: Up to Week 52

  10. Exploratory - Proportion of Participants Receiving Red Blood Cells (RBCs) Transfusion(s)

    Time frame: Up to Week 52

07

Results

Posted Jul 18, 2022

Participant flow

Participant flow — Overall Study
MilestoneVadadustatDarbepoetin Alfa
Started181188
Completed160165
Not completed2123
Withdrew: Death1519
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up32

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)

The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (\<9.5 versus ≥9.5 g/dL), geographic region (United States \[US\] versus European Union \[EU\] versus Rest of World \[ROW\]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 \[no CHF\] or I versus II or III) as covariates.

Time frame:
Baseline; Weeks 24 to 36
Reported as:
Least squares mean · Grams per deciliter (g/dL)
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Grams per deciliter (g/dL)VadadustatDarbepoetin Alfa
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)1.26 ± 0.1091.58 ± 0.108
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Least squares mean difference: -0.31 · 95% CI -0.53 to -0.10
PrimaryMedian Time to First Major Adverse Cardiovascular Event (MACE)

MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 176 weeks
Reported as:
Median · Weeks
Median Time to First Major Adverse Cardiovascular Event (MACE)
WeeksVadadustatDarbepoetin Alfa
Median Time to First Major Adverse Cardiovascular Event (MACE)26.21 (13.71 to 50.00)46.64 (22.86 to 58.14)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.9950 · Hazard ratio (hr): 0.97 · 95% CI 0.536 to 1.761Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4877 · Hazard ratio (hr): 0.96 · 95% CI 0.833 to 1.113Based on non-parametric analysis.
SecondaryChange From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)

The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (\<9.5 versus ≥9.5 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 \[no CHF\] or I versus II or III) as covariates.

Time frame:
Baseline; Weeks 40 to 52
Reported as:
Least squares mean · g/dL
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
g/dLVadadustatDarbepoetin Alfa
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)1.42 ± 0.1321.50 ± 0.136
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Least squares mean difference: -0.07 · 95% CI -0.34 to 0.19
SecondaryMedian Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis

MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 176 weeks
Reported as:
Median · Weeks
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
WeeksVadadustatDarbepoetin Alfa
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis27.14 (14.14 to 46.14)47.00 (21.86 to 61.57)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.8871 · Hazard ratio (hr): 1.04 · 95% CI 0.618 to 1.743Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4096 · Hazard ratio (hr): 0.96 · 95% CI 0.840 to 1.096Based on non-parametric analysis.
SecondaryMedian Time to First Cardiovascular MACE

MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 176 weeks
Reported as:
Median · Weeks
Median Time to First Cardiovascular MACE
WeeksVadadustatDarbepoetin Alfa
Median Time to First Cardiovascular MACE18.50 (11.29 to 34.43)54.07 (35.29 to 67.00)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.5210 · Hazard ratio (hr): 1.36 · 95% CI 0.670 to 2.771Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.5007 · Hazard ratio (hr): 0.95 · 95% CI 0.795 to 1.144Based on non-parametric analysis.
SecondaryMedian Time to First Cardiovascular Death

Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 176 weeks
Reported as:
Median · Weeks
Median Time to First Cardiovascular Death
WeeksVadadustatDarbepoetin Alfa
Median Time to First Cardiovascular Death22.00 (12.71 to 33.14)58.14 (21.86 to 67.57)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.9527 · Hazard ratio (hr): 1.10 · 95% CI 0.452 to 2.666Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.6284 · Hazard ratio (hr): 0.96 · 95% CI 0.766 to 1.195Based on non-parametric analysis.
SecondaryMedian Time to First All-cause Mortality

Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0016 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 176 weeks
Reported as:
Median · Weeks
Median Time to First All-cause Mortality
WeeksVadadustatDarbepoetin Alfa
Median Time to First All-cause Mortality31.71 (13.71 to 62.00)45.36 (21.57 to 58.14)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.5115 · Hazard ratio (hr): 0.78 · 95% CI 0.388 to 1.555Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4878 · Hazard ratio (hr): 0.95 · 95% CI 0.812 to 1.118Based on non-parametric analysis.
Other pre-specifiedExploratory - Proportion of Participants With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)
Time frame:
Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Time With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)
Time frame:
Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Time With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)
Time frame:
Weeks 40 to 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)
Time frame:
Weeks 40 to 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants With an Hb Increase of >1.0 g/dL From Baseline Visit
Time frame:
Baseline; up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Time to Achieve Hb Increase of >1.0 g/dL From Baseline Visit
Time frame:
Baseline; up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Mean Change in Hb Between Baseline (Mean Pretreatment Hb) and the Primary Evaluation Period (Mean Hb From Weeks 24 to 36) Stratified by Pre-baseline Erythropoiesis-stimulating Agent (ESA) Exposure
Time frame:
Baseline; Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Mean Monthly Dose of Intravenous (IV) Elemental Iron Administered in Participants Who Have Received IV Iron
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants Receiving IV Iron Therapy
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants Receiving Red Blood Cells (RBCs) Transfusion(s)
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Adverse events

Collected over Up to 176 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat15/179 (8.4%)89/179 (49.7%)79/179 (44.1%)
Darbepoetin Alfa20/186 (10.8%)105/186 (56.5%)83/186 (44.6%)
Most frequent serious events
Showing 10 of 257
Most frequent serious events
EventVadadustatDarbepoetin Alfa
Fluid overloadMetabolism and nutrition disorders10/1792/186
PneumoniaInfections and infestations8/1797/186
Hypertensive urgencyVascular disorders7/1793/186
SepsisInfections and infestations3/1796/186
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications3/1796/186
HyperkalaemiaMetabolism and nutrition disorders5/1794/186
Acute respiratory failureRespiratory, thoracic and mediastinal disorders5/1794/186
Coronary artery diseaseCardiac disorders4/1794/186
OsteomyelitisInfections and infestations4/1794/186
CellulitisInfections and infestations4/1792/186
Most frequent other events
Showing 10 of 15
Most frequent other events
EventVadadustatDarbepoetin Alfa
HypertensionVascular disorders27/17924/186
DiarrhoeaGastrointestinal disorders18/17917/186
Urinary tract infectionInfections and infestations9/17916/186
HypotensionVascular disorders5/17916/186
NauseaGastrointestinal disorders14/17913/186
DyspnoeaRespiratory, thoracic and mediastinal disorders13/17910/186
VomitingGastrointestinal disorders13/1799/186
ConstipationGastrointestinal disorders3/17913/186
Procedural hypotensionInjury, poisoning and procedural complications11/17912/186
CoughRespiratory, thoracic and mediastinal disorders11/1795/186

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VadadustatDarbepoetin AlfaTotal
Mean56.5 ± 14.8055.6 ± 14.6056.0 ± 14.69
Sex: Female, Male
Sex: Female, Male(Participants)VadadustatDarbepoetin AlfaTotal
Female7475149
Male107113220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VadadustatDarbepoetin AlfaTotal
American Indian or Alaska Native101
Asian12820
Black or African American383573
White129143272
Not Reported011
Reported as Other011
Multiple101
Average hemoglobin
Average hemoglobin(Grams per deciliter (g/dL))VadadustatDarbepoetin AlfaTotal
Mean9.369 ± 1.07019.190 ± 1.13819.278 ± 1.1074
Number of Participants on Different Types of Dialysis
Number of Participants on Different Types of Dialysis(Participants)VadadustatDarbepoetin AlfaTotal
Peritoneal Dialysis221638
Hemodialysis158169327
Chronic Dialysis Not Previously Initiated112
Mean Years Since Chronic Dialysis Initiated
Mean Years Since Chronic Dialysis Initiated(Years)VadadustatDarbepoetin AlfaTotal
Mean0.138 ± 0.08830.151 ± 0.28480.145 ± 0.2123
Number of Participants with History of Diabetes
Number of Participants with History of Diabetes(Participants)VadadustatDarbepoetin AlfaTotal
Count of participants8182163
Number of Participants with NYHA Functional Classification of Heart Failure
Number of Participants with NYHA Functional Classification of Heart Failure(Participants)VadadustatDarbepoetin AlfaTotal
NYHA Class 0129126255
NYHA Class I303565
NYHA Class II182341
NYHA Class III347
NYHA Class IV000
NYHA Class Missing101

1 further baseline measures are reported on the registry.

08

Study locations

118 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Mesa, Arizona 85210, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Canyon Country, California 91387, United States
  • Research Site
    Downey, California 90240, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Long Beach, California 92886, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Montebello, California 90640, United States
  • Research Site
    Monterey Park, California 91754, United States
  • Research Site
    Newhall, California 91321, United States
  • Research Site #1
    Northridge, California 91324, United States
  • Research Site #2
    Northridge, California 91324, United States
  • Research Site
    Riverside, California 92503, United States
  • Research Site
    Riverside, California 92505, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    San Diego, California 92115, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Westminster, Colorado 80031, United States
  • Research Site
    Stamford, Connecticut 06902, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Coral Springs, Florida 33071, United States
  • Research Site
    Lauderdale Lakes, Florida 33313, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Miami, Florida 33150, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Augusta, Georgia 30904, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site #2
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Statesboro, Georgia 30458, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Takoma Park, Maryland 20912, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    Astoria, New York 11102, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site #1
    Chattanooga, Tennessee 37408, United States
  • Research Site #2
    Chattanooga, Tennessee 37408, United States
  • Research Site
    Knoxville, Tennessee 37923, United States
  • Research Site
    Nashville, Tennessee 37205, United States
  • Research Site
    Arlington, Texas 76015, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Houston, Texas 77054, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    San Antonio, Texas 78212-4740, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Hampton, Virginia 23666, United States
  • Research Site
    Bahia Blanca, Buenos Aires B8001HXM, Argentina
  • Research Site
    Ciudad Autonoma Buenos Aires, Buenos Aires C1181ACH, Argentina
  • Research Site
    Junin, Buenos Aires 6000, Argentina
  • Research Site
    Pergamino, Buenos Aires B2700CPM, Argentina
  • Research Site
    Temperley, Buenos Aires 1834, Argentina
  • Research Site
    Cordoba, 5000, Argentina
  • Research Site
    Corrientes, 3400, Argentina
  • Research Site
    Salta, A4400AXO, Argentina
  • Research Site
    San Luis, 5700, Argentina
  • Research Site
    Fortaleza, Ceará 60430-370, Brazil
  • Research Site
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Research Site
    Juiz de Fora, Minas Gerais 36036-330, Brazil
  • Research Site
    Curitiba, Paraná 80010-030, Brazil
  • Research Site
    Maringá, Paraná 87060-040, Brazil
  • Research Site
    Canoas, Rio Grande Do Sul 92425-900, Brazil
  • Research Site
    Passo Fundo, Rio Grande Do Sul 99010-080, Brazil
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90035-074, Brazil
  • Research Site
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Research Site
    Joinville, Santa Catarina 89202-050, Brazil
  • Research Site
    Santo André, Sao Paulo 09090-790, Brazil
  • Research Site
    São Bernardo do Campo, Sao Paulo 09715-090, Brazil
  • Research Site
    São Paulo, Sao Paulo 04039-000, Brazil
  • Research Site
    Villingen-Schwenningen, Baden Wuerttemberg 78054, Germany
  • Research Site
    Rostock, Mecklenburg Vorpommern 18057, Germany
  • Research Site
    Duesseldorf, Nordrhein Westfalen 40210, Germany
  • Research Site
    San Giovanni Rotondo, Foggia 71013, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Lecco, 23900, Italy
  • Research Site
    Napoli, 80138, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Roma, 168, Italy
  • Research Site
    Siena, 53100, Italy
  • Research Site
    Chuncheon, Gangwon-do 200-702, Korea, Republic of
  • Research Site
    Seongnam-si,, Gyeonggi-do 13496, Korea, Republic of
  • Research Site
    Busan, 47392, Korea, Republic of
  • Research Site
    Seoul, 6591, Korea, Republic of
  • Research Site
    Seoul, 7345, Korea, Republic of
  • Research Site
    Zapopan, Jalisco 45030, Mexico
  • Research Site
    Morelia, Michoacán 58260, Mexico
  • Research Site
    Culiacan, Sinaloa 80230, Mexico
  • Research Site
    Golub Dobrzyn, 87-400, Poland
  • Research Site
    Lodz, 90-153, Poland
  • Research Site
    Lodz, 92-213, Poland
  • Research Site
    Leiria, 2400-441, Portugal
  • Research Site
    Loures, 2674-514, Portugal
  • Research Site #2
    Kemerovo, 650066, Russian Federation

Showing the first 100 of 118 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956. PubMed 33913638 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Jan 2020, 42 months.

Results were first posted in Jul 2022, 2 years 5 months after primary completion. A results delay was requested in Jan 2021.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 42 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 15, 2016
StartActual
Jul 2016
Primary completionActual
Jan 31, 2020
CompletionActual
Mar 30, 2020
Results delay requested
Jan 29, 2021
Results first posted
Jul 18, 2022
Last update
Jul 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02865850
Responsible party
Sponsor
First posted
Aug 15, 2016
Start date
Jul 2016
Primary completion
Jan 31, 2020
Completion
Mar 30, 2020
Results posted
Jul 18, 2022
Last update
Jul 18, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion